Ask Warren

Kyongbo Pharmaceutical

214390 · KOSPI · ₩214390 · 경보제약

₩5,140▼ ₩10 (0.19%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩75B₩66B₩71B₩67B₩65B₩61B₩59B₩58B
Cost of sales₩47B₩39B₩44B₩42B₩36B₩39B₩36B₩38B
Gross profit₩29B₩27B₩27B₩25B₩29B₩22B₩23B₩20B
Operating income₩930M₩713M₩516M₩474M₩2.4B₩121M₩3B₩3.2B
Net income₩3.5B−₩530M−₩2.8B₩4.8B−₩1B−₩695M₩3.6B₩925M
Net income to shareholders₩3.5B−₩530M−₩2.8B₩4.8B−₩1B−₩695M₩3.6B₩925M

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩368B₩339B₩320B₩316B₩312B₩288B₩284B₩280B
Current assets₩170B₩157B₩159B₩157B₩161B₩151B₩152B₩151B
Cash and equivalents₩6.9B₩5.2B₩7.2B₩2.6B₩2.6B₩1.9B₩4.1B₩345M
Total liabilities₩221B₩195B₩174B₩171B₩170B₩144B₩138B₩134B
Current liabilities₩194B₩167B₩147B₩166B₩165B₩139B₩133B₩130B
Borrowings₩155B₩140B₩125B₩122B₩110B₩96B₩89B₩0
Total equity₩147B₩144B₩146B₩145B₩142B₩144B₩146B₩146B
Shareholders' equity₩147B₩144B₩146B₩145B₩142B₩144B₩146B₩146B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩565M₩1.8B₩6.2B₩4.5B−₩1.3B−₩2B₩5.7B−₩1.3B
Capital spending₩16B₩15B₩75B−₩17B−₩23B₩5.8B₩3B₩3.4B
Free cash flow−₩17B−₩13B−₩69B−₩13B−₩24B−₩7.8B₩2.6B−₩4.7B
Dividends paid₩0₩1.2B₩2.4B₩0−₩1.2B₩0₩0₩0

Consolidated where available. Amounts in won.

Also known as: Kyongbo Pharmaceutical / 경보제약 / 214390 / KRX:214390

Source: KRX statistical information